One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

Continue advancement of MRT-6160 through Phase 2 initiation, in collaboration with Novartis. Share additional MRT-2359 Phase 1/2 study data in ...

Monte Rosa Therapeutics, Inc.’s GLUE share price has dipped by 17.85%, which has investors questioning if this is right time ...

This was accompanied by downregulation of key cell cycle proteins such as CDK2, Cyclin A2, CDK4/6, and Cyclin D1/E1 complexes. Additionally, ferulic acid upregulated tumor suppressor proteins p53 ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

Beigene Switzerland GmbH has divulged CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer. New CDK2/cyclin E1 inhibitors disclosed in Beigene patent | BioWorld BioWorld.

Genentech Inc. has disclosed molecular glue compounds with the ability to induce cyclin-dependent kinase 2 (CDK2)/protein cereblon (CRBN) interaction for CDK2 degradation reported to be useful for the ...

NiKang noted that the orally bioavailable small molecule NKT3964 selectively degrades cyclin-dependent kinase 2 (CDK2). NiKang Therapeutics president, co-founder and CEO Zhenhai Gao said: “Completing ...